Amgen Inc. (AMGN) Q1 2026 (USD): Adj. EPS 5.15 (exp. 4.77), Revenue 8.62bln (exp. 8.58bln)
Outlook
- FY adj. EPS 21.70-23.10 (exp. 22.33).
- FY revenue 37.1-38.5bln (exp. 37.8bln).
Context
Amgen's Q1 results came in better than expected, with both adjusted EPS and revenue surpassing estimates. This strong performance, alongside a promising fiscal year outlook, could positively influence sentiment toward the biotech sector and support the stock's performance against peers.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#AMGEN INC#AMGN.US#FOREX#EQUITIES#METALS#US SESSION#BIOTECHNOLOGY#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#AMGN#DXY#US EQUITIES